An Open-label Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activit of TAK-500 a Novel Stimulator of Interferon Genes Agonist as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Renal Cell Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients with the following pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic RCC. Patients who are intolerant to all standard therapies are those who have developed clinical or laboratory abnormalities that prevent continued drug administration as evaluated by the principal investigator at the time of screening
    2. Patients may not have a known targetable driver mutation, rearrangement or amplification (eg, EGFR, ALK, MET, ROS1, BRAF, KRASG12C, etc.

You may not be eligible for this study if the following are true:

    1. Been treated with other STING agonists/antagonists, Toll-like receptor agonists, or CCR2 agonist/antagonist within the past 6 months
    2. Active diagnosis of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade =2 pleural effusion not controlled by tap or requiring indwelling catheters
    3. History of brain metastasis or leptomeningeal disease



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.